Preventive Medical Solutions Integrate With Major Cannabis Providers for Innovative Drug Delivery

NEW YORK, March 14, 2018 /PRNewswire/ --

NetworkNewsWire Editorial Coverage 

As the legal cannabis market continues to grow, new deals are creating opportunities for a range of companies and an influx of investments. PreveCeutical Medical, Inc. (CSE: PREV) (OTC: PRVCF) (FSE: 18H) (PRVCF Profile) has teamed up with research institutions in Australia and gained a government permit to import cannabis for development of its drug delivery system. Cannabis for this project will be supplied by Aurora Cannabis (OTC: ACBFF) (TSX: ACB), a company experiencing significant production growth, including a deal for a new joint venture in Denmark. ABcann Global (TSX-V: ABCN) (OTC: ABCCF) (ABCCF Profile) is expanding its production facilities and utilizing a computer-controlled system to ensure the best growing conditions, while Aphria, Inc. (TSX: APH) (OTC: APHQF) has developed an expansion strategy using targeted investment and collaborations to help the company and its partners grow. And with legal recreational cannabis coming to Canada, Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) has secured a $191 million investment from Constellation Brands to support new products such as cannabis-infused soft drinks.

Demand for Cannabis Grows

The cannabis market is growing fast as more states and countries legalize its use for both medical and recreational purposes. This is allowing companies to invest heavily in cannabis research to develop drugs and other products for this growing market. Research and design is becoming increasingly important.

Research for Preventive Treatment

One of the companies deeply involved in this process is PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H). The company was founded by entrepreneurs Stephen Van Deventer and Kimberly Van Deventer. The pair has been working together since they created business development and venture capital company Cornerstone Global Partners in 2009. Since then they have helped create successful cannabis, hemp and block-chain companies.

Building on a shared interest in the health and wellness market, they began research into pairing natural remedies with scientific achievement to provide treatments for health-conscious consumers. In October 2015 they formed PreveCeutical, combining the words "preventive" and "pharmaceutical" to express the company's goal: medicinally preventing illnesses.

The company's products are designed to help people stay healthy rather than dealing with the consequences of illnesses when they hit. Its therapies, both preventive and curative, use organic and Nature Identical™ products to ensure that they are in harmony with natural forces and appealing to environmentally and ethically conscious consumers. Initial research and product development has focused on medically acute ailments such as Type 2 diabetes, obesity, cancer, neurological disorders and pain management.

Focus on Research

PreveCeutical Medical's corporate office is based in Canada, and it is making bold advances through research partnerships and a research team based in Australia. One of its main partners is UniQuest, the University of Queensland's commercialization company. The partnership gives PreveCeutical the rights to any intellectual property created through work under their agreement. University of Queensland's scientific knowledge and experience in intellectual property management combined with PreveCeutical's extensive experience in product development, corporate strategy and accessing capital markets, creates a powerful combination of academic and commercial expertise.

Chief Research Officer Dr. Harry Parekh will lead the sol-gel cannabinoid project from his base at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE) and is joined by Chief Science Officer Dr. Makarand Jawadekar, who has 28 years of experience in R&D with Pfizer, Inc. Dr. Jawadekar was a part of the team responsible for bringing drugs such as Zolof and Viagra to the market. They are supported by research collaborators Dr. Rakesh Veedu and professor Grant Ramm. Dr. Veedu is an emerging international expert in molecular medicine, while professor Ramm is currently head of a leading medical research institute in Brisbane, Australia.

Cannabis Plant Material in Medical Research

PreveCeutical's work extends to one of the most exciting and fastest growing areas of medical research - the use of cannabidiols (CBDs).

PreveCeutical and Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB) recently announced the grant of three permits by the Australian Department of Health for the import of CBDs for research purposes (http://nnw.fm/K2l88). The CBD will go to PACE at the University of Queensland, where it will be used in a research program led by Dr. Parekh. This program will be built around PreveCeutical's sol-gel nasal drug delivery system. The aim is to develop sol-gels that deliver CBDs - active, non-psychotropic ingredients from cannabis - more effectively into the patient's system. CBDs can provide valuable solutions for a wide range of symptoms including pain, inflammation, seizures and neurological disorders. The research team's hope is that, through a more direct nose-to-brain delivery system, they can provide faster, more effective relief using a time-release, nano bubble technology.

Notably, the cannabis will be provided by Aurora Cannabis. A licensed producer under the Canadian government's medical cannabis regulations, Aurora has over 175,000 square feet of production facilities. These allow it to provide large volumes of high-grade medical cannabis for customers such as PreveCeutical.

Better Ways to Deliver Medicine

The sol-gel delivery system is one of the most exciting developments to come out of PreveCeutical's medical research program. It provides medicine in a liquid form that is squirted up the nose. There, it forms a gel that slowly and steadily releases the active ingredients over time.

Sol-gel gets around barriers within the body that limit the effectiveness of drugs targeting the brain. Traditional delivery methods, including pills and injections, go through a complex range of bodily systems before reaching the target. The liver filters out and metabolizes ingredients, affecting both effectiveness and delivery time. The blood-brain barrier blocks the path for active ingredients to reach the brain.

Sol-gel uses hydrogels-molecules that soak up biological fluids and closely resemble living tissue. Sprayed onto the nasal mucosa, the medicine has a more direct route to the brain, bypassing bodily barriers and increasing the effectiveness of the treatment. The gel's controlled release of medicine means that delivery is steady as well as direct, reducing daily doses to once or twice a week with a 90 percent bioavailability.

Supplying a Growing Research Business

ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) is another company gaining traction in its cannabis business. The company runs a production facility in Ontario with 14,500 square feet of growing space. Its computer-controlled environment uses proprietary lighting systems designed to replicate the natural environment and provide a perfect space for cannabis to grow. ABcann also owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to 1 million square feet, and is pursuing ongoing global expansion into the European, Australian and Israeli markets.

Canadian companies are using their experience and favorable market conditions to expand into other cannabis markets. Aphria (TSX: APH) (OTCQB: APHQF), a Canadian medical cannabis company, is working in not only the Canadian but also the American market. Its strategy of collaboration and targeted investment has led to significant expansion. This includes a recent agreement with the Société des alcools du Québec (SAQ) to supply high-quality cannabis products through retail outlets in Quebec and an associated e-commerce platform.

Canopy Growth (TSX: WEED) (OTC: TWMJF) has achieved an even bigger team-up through an agreement with Constellation Brands. The $42 billion company is behind the Corona, Modelo and Svedka brands and has taken a $191 million stake in Canopy Growth, providing investment for the development of cannabis-related soft drinks. Canopy Growth's other collaborations include a deal with Sunniva, a vertically integrated cannabis company focused on the Canadian and Californian markets. This deal will see a steady supply of cannabis for Canopy Growth, allowing it to expand its share of the market.

Research is leading the way in the cannabis market, with the development of new drugs and recreational products. That research is powering fresh growth on the production side for a sector that's healthier than ever before.

For more information on PreveCeutical Medical Inc., visit PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H).

About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).

About IBN
Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Please feel free to visit the Investor Brand Network (IBN) www.InvestorBrandNetwork.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York
+1-212-418-1217 Office
[email protected]

Media Contact:
FN Media Group, LLC
[email protected]  
+1-(954)345-0611

SOURCE NetworkNewsWire